The glycine receptor (GlyR) is a member of the cys-loop superfamily of ligand-gated ion channels and the major mediator of inhibitory neurotransmission in the spinal cord and brainstem. Many allosteric modulators affect the functioning of members of this superfamily, with some like benzodiazepines showing great specificity, while others such as zinc, alcohols and volatile anesthetics act on multiple members. To date no potent and efficacious allosteric modulator acting specifically at the GlyR has been identified, hindering both experimental characterization of the receptor as well as the development of GlyR-related therapeutics. We used phage display to identify novel peptides that specifically modulate GlyR function. Peptide D12-116 markedly enhanced GlyR currents at low micromolar concentrations, but had no effects on the closely-related GABA A receptors. This approach can readily be adapted for use with other channels that currently lack specific allosteric modulators.
The glycine receptor is a member of the cys-loop superfamily of ligand-gated ion channels, including also the GABA A and 5-HT 3 receptors. They share a number of structural features including ligand-binding sites in the extracellular N-terminal domain and a transmembrane (TM) domain consisting of 4 segments, with a large intracellular loop connecting segments three and four. Individual channels consist of five subunits co-localized with the TM2 segment of each subunit lining the anion-conducting pore (1, 2) . Two classes of glycine receptor subunits have been identified: the α subunits, of which there are 4 subtypes, and a single β subunit (3) . Most native GlyRs in adult animals consist of heteromeric α1β subunits, although homomeric α2 receptors are the predominant form found prenatally (4) . Glycine receptors constitute the major inhibitory neurotransmitter receptor system in the brainstem and spinal cord (5) , where they are thought to play a role in the modulation of pain signals and in the effects of volatile anesthetics (1) . Some GlyR mutations result in the startle disorder hyperekplexia. GlyRs are also found throughout the brain including the thalamus, hippocampus, and nucleus accumbens, where they were recently shown to be involved in the reinforcing properties of ethanol (6) . The GlyR is only one of multiple ion channels and receptors thought to play a role in pain perception, alcohol and volatile anesthetic effects, and in determining the state of neuronal excitability. The isolation of the GlyR's role is hindered by the fact that, to date no potent and efficacious allosteric modulator acting specifically at the GlyR has been identified. Phage display involves the expression of a random library of peptides on the coat proteins of bacteriophage. This method has long been used to identify peptides that can bind with high affinity to selected targets and aid in identifying binding motifs (7) . We combined phage display technology with standard electrophysiological testing to identify peptides that allosterically modulate GlyR function without affecting two closely-related GABA receptors. phage from the D-12 phage library (New England Biolabs) was diluted in 1 mL of PBS/BSA+T. Phage were then applied to blank (control) HEK 293 cells and rocked gently at room temperature for 30 minutes. Phage that did not bind in this negative selection procedure were removed from the plate with a pipette, applied to the plate of GlyR-expressing cells and rocked gently at room temperature for 60 minutes. Non-binding phage were discarded and the plate washed five times with PBS/BSA+T. At this time positive selection was complete and the only step remaining was the isolation of phage. Elution of the bound phage was performed by lowering the pH using 0.2 M glycine-HCl (10 M HCl buffered to pH 2.2 with glycine) plus 1 mg/ml BSA and rocking at room temperature for 10 minutes. Eluate was removed and neutralized with 150 µl of 1 M Tris-HCl (pH 9.0). Titering was performed and the remainder of the eluate was added to the 20 mL of OD 600 E.coli in LB broth. After 4.5 hours of incubation the culture was transferred to a 50 mL Falcon centrifuge tube and spun at 10,000 rpm for 10 min at 4 o C. The supernatant was transferred to a fresh tube and respun. The upper 80% of the supernatant was again transferred to a fresh tube and a 1/6 th volume of PEG/NaCl (20% w/v polyethylene glycol-8000, 2.5 M NaCl) added. Phage were allowed to precipitate overnight at 4 o C. Panning day two: PEG precipitates were spun for 15 min at 10,000 rpm at 4 o C. The supernatant was decanted and the precipitate spun again. Residual supernatant was removed using a pipette. The pellet was resuspended in 1 ml of tris-buffered saline (50 mM Tris-HCl at pH 7.5, 150 mM NaCl), transferred to a 1.7 ml microcentrifuge tube, and spun at 10,000 rpm for 5 min at 4 o C. In a fresh microcentrifuge tube, the suspended phage was re-precipitated with PEG/NaCl on ice for 60 min. After spinning at 10,000 rpm for 10 min at 4 o C the supernatant was discarded. The pellet was resuspended in TBS and spun again for 1 min and the supernatant then transferred to a fresh tube and stored at 4 o C. The amplified phage were then titered. For successive panning rounds, the amplified phage were diluted in PBS/BSA + T so that the input concentration was always 2 x 10 11 virions. At the end of five rounds of panning, individual plaques from the most recent titer plates were isolated and incubated overnight in LB broth at 37 o C with agitation. The overnight culture was then purified using the S.N.A.P. mini-prep kit (Invitrogen) and phage DNA sequenced in-house using a -96gIII sequencing primer (New England Biolabs). Individual peptide sequences were sent to Peptide 2.0 (Chantilly, VA) for synthesis. Oocyte isolation and cDNA nuclear injectionOoctyes were surgically removed from Xenopus laevis housed at 19 o C on a 12hr light/dark cycle. Stage V and VI oocytes were selected and placed in isolation media containing 108 mM NaCl, 1 mM EDTA, 2 mM KCl, and 10 mM HEPES, and forceps were used to manually remove the thecal and epithelial layers. The oocyte follicular layer was removed using a 10 minute exposure to 0.5 mg/ml Sigma type 1A collagenase in buffer containing 83 mM NaCl, 2 mM MgCl 2 , and 5 mM HEPES. Injection of a 30 nl sample of the glycine or GABA receptor subunit cDNAs (1.5 ng/30 nl) in a modified pBK-CMV vector (9) was made into the animal poles of oocytes by the "blind" method of Colman (10), using a digital micropipette (10 -15 µm tip size) attached to a microdispenser. Oocytes were stored in 96-well plates in the dark at 19°C in Modified Barth's Saline (MBS) [88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO 3 , 10 mM HEPES, 0.82 mM MgSO 4 ּ◌7H 2 O, 0.33 mM Ca(NO 3 ) 2 , 0.91 mM CaCl 2 at pH 7.5] plus 2 mM sodium pyruvate, 0.5 mM theophylline, 10 U/ml penicillin, 10 mg/l streptomycin, and 50 mg/l gentamycin, sterilized by passage through a 0.22 micron filter. Oocytes expressed channels within 24-96 hours, depending on receptor expressed, and all electrophysiological measurements were made within 5 days of cDNA injection.
Oocyte electrophysiological recording -Oocytes were impaled in the animal poles with two highresistance (0.5-10 MΩ) glass electrodes filled with 3 M KCl. Using a Warner Instruments OC-725C oocyte-clamp (Hamden, CT), oocytes were voltage-clamped at -70 mV while MBS was perfused over them at a rate of 2 ml/min using a Masterflex USA peristaltic pump (Cole Parmer Instrument Co, Vernon Hills, IL) through 18-gauge polyethylene tubing. All drug solutions were prepared in MBS. Drug applications (5-60 sec) were followed by 5-15 minute washout periods as appropriate. Statistics -Current peak responses were measured from chart recorder tracings. Peptide effects were calculated as percent changes compared to the effects produced by glycine or GABA in the absence of peptide. In all cases, oocyte data were obtained from at least two different frogs. The percent enhancement or inhibition values obtained in the presence of peptide were compared by either one-way or two-way ANOVAs, as indicated, to determine statistical significance, with a criterion of p<0.05 required.
RESULTS
We used a commercially-available phage display library, expressing more than two billion unique sequences, to isolate peptides that bind to α1 GlyR expressed in HEK 293 cells. The homomeric α1 GlyR was chosen as the target rather than the heteromeric α1β GlyR because of its invariant stoichiometry: heteromeric α1β receptors contain αα, αβ and βα inter-subunit interfaces. In addition we wanted to avoid the possible complication that some receptors in our population were α1 homomers while others were α1β heteromers. A modified phage display protocol (11) involved first applying phage to untransfected HEK 293 cells in the negative selection step to remove those phage that bound to various endogenous targets that were not of interest. Phage that did not bind in this negative selection procedure were then applied to HEK 293 cells that expressed the GlyR α1 subunit, and this constituted the positive selection portion of the procedure. After five rounds of panning, 35 individual colonies were sequenced to identify the peptides inserted in the phage pIII protein that resulted in phage binding (Table 1) . Three sequences were harvested from multiple colonies, implying selective enrichment of our phage pool. No clear homology was seen among the collected sequences. Due to the size of the extracellular domain of the GlyR and thus a large number of potential binding sites, this diversity of peptide sequences was not unexpected.
Peptides corresponding to 10 sequences were synthesized for characterization using twoelectrode voltage-clamp electrophysiology. A maximally-effective concentration of glycine (10 mM) was first applied to Xenopus oocytes to determine their levels of expression of GlyR two days after GlyR α1 subunit cDNA injection. A low concentration of glycine eliciting a response equal to approximately 10 percent of the maximal current (EC10) was identified in each oocyte and applied several times to ensure stability of responses. The oocyte was then incubated with 30 µM of a peptide for 30 seconds before coapplication of peptide with EC10 glycine. If peptides failed to show an effect at 30 µM they were not tested further. This does not eliminate the possibility that effects might be seen at higher concentrations; however, these peptides would not be as interesting as those that were more potent. None of the peptides tested thus far had any effects in the absence of glycine implying that they neither function as agonists at the orthosteric glycine binding site nor affect the functioning of any other naturally-occurring oocyte proteins that might influence the holding current. Some peptides, such as D12-106, inhibited the effects of glycine (Fig. 1a) while others, such as D12-105, acted as positive modulators (Fig. 1b) . The 10 peptides tested thus far exhibited a variety of effects on GlyR function, ranging from 65% inhibition to 124% potentiation of the effects of EC10 glycine (Fig. 1c) .
Although our peptides were chosen based on their abilities to bind to the GlyR, there was a chance they might also affect structurally similar channels. The cys-loop receptor superfamily possesses considerable structural and sequence homology among its members (12) . Within the superfamily, the GlyR is most similar to the other anion-conducting channels. Of these the GABA ρ1 subunit is the most similar to the GlyR α1, with approximately 60% amino acid sequence identity (13), followed by other members of the GABA A group (14) . For specificity testing we compared peptide effects on the α1 GlyR with those on homomeric GABA ρ1 and heteromeric α1β2γ2S receptors. While many types of GABA A receptors exist, those comprised of α1, β2 and γ2S subunits are most widely expressed in the adult nervous system. As with the GlyR experiments, oocytes expressing these channels were voltageclamped at -70 mV and the EC10 GABA concentration established. Figures 2a and 2b show sample tracings of the effects of peptides D12-106 and D12-133 on EC10 GABA responses generated by α1β2γ2S receptors. D12-106 produced minor inhibition of GABA A receptor function, far smaller than its effects on the GlyR, while D12-133 was almost completely without effect. None of the five peptides tested on GABA A receptors produced marked effects (Fig.  2c) . Furthermore, none applied alone affected holding currents and thus did not function as agonists at the GABA binding site.
Peptide D12-116 produced a marked enhancement of GlyR function while not affecting α1β2γ2S GABA A receptors. Figure 3a shows a sample tracing of the current-enhancing effects of a 30 µM concentration of peptide D12-116 on α1 GlyR. In contrast this concentration of peptide had no effects when co-applied with an EC10 concentration of GABA on α1β2γ2S receptors (Fig. 3b) or homomeric GABA ρ1 receptors (Fig.  3c) . Neither GABA receptor showed any effects of 30 µM D12-116, as summarized in Figure 3d . A 100 µM concentration of D12-116 was also without effect on both GABA receptors, implying that this result is due to true specificity at the GlyR rather than due to potential differences in peptide potency among cys-loop receptors. Since this peptide does not affect the channels most structurally similar to the GlyR, it is unlikely to have effects on even more distantly related targets.
A concentration-response curve was next performed using peptide D12-116 (Fig. 4a ). When applied with EC10 glycine, the threshold concentration of D12-116 eliciting an enhancing effect was approximately 3 µM, with 40 µM D12-116 producing a maximal effect; higher concentrations were less efficacious. This could imply that at higher concentrations this peptide forms dimers with lower efficacy or that multiple binding sites with different affinities for this peptide exist on the GlyR. We then showed that 30 µM D12-116 acts to left-shift the glycine concentration-response curve without any effect at saturating glycine concentrations (Fig. 4b) . This result is in concordance with previous studies showing that other allosteric modulators of the GlyR, such as alcohols, volatile anesthetics and low concentrations of zinc also act by left-shifting glycine concentration-response curves (15, 16, 17) .
DISCUSSION
One of the most pharmacologically relevant of the proposed roles of the GlyR in vivo is the one it may play in alcohol-induced behaviors. Many cell-surface proteins, such as voltage-and ligandgated ion channels, enzymes and transporters have been implicated as possible mediators of the effects of ethanol, but the relative importance of each putative target to the effects of alcohol in vivo remains poorly understood (18) . A major impediment to the rational identification of compounds to treat alcohol abuse is this lack of understanding of which of these many possible molecular targets mediate which specific in vivo effects of alcohol, such as reinforcement, ataxia or the development of tolerance. Enhancement of inhibitory GlyR function by ethanol is consistent with some of the behavioral consequences of its administration (6, 19) . However, because ethanol clearly affects multiple biochemical targets in addition to the GlyR, it has proved difficult to determine conclusively the roles that individual putative targets play in the various behavioral effects of this agent. There would thus be great utility in identifying compounds that can act as either mimics of ethanol, or as ethanol antagonists, but at only one putative alcohol target. For example, were we to administer our D12-116 peptide intrathecally to rats and observe ataxia, it would suggest that ataxia produced by ethanol is also mediated by enhancement of GlyR function. While studies using knock-out and knock-in mice (20) have provided some successes, these methods due to their nature, necessarily involve a departure from the wild-type target phenotype. An alternative approach is the highly specific pharmacological manipulation of individual targets. Allosteric modulation offers the opportunity for subtle manipulations of a target, rather than complete removal or blockade. Our identification of a GlyR-specific enhancing peptide allows one to emulate the effects of ethanol at just this one site. Thus, the identification of agents that modulate or mimic ethanol or volatile anesthetic actions at targets with high specificity could allow for the determination of the contributions of those sites to the effects of these compounds without requiring one to alter wild-type baseline GlyR function. A better understanding of the relative importance of individual targets could also lead to the development of more targeted therapeutics. This rational approach to drug discovery contrasts markedly with the serendipitous approach to the identification of drugs currently used in the treatment of alcoholism.
There are many instances of small molecules acting as specific allosteric modulators of proteins (21 22) . For example, benzodiazepines bind at nM concentrations to GABA A receptors containing specific subunits. There they can act as agonists, inverse agonists or antagonists at a site distinct from the GABA binding site to modulate GABA A receptor-mediated currents, but they exert no effects if applied on their own (23) . Allosteric modulators at G-protein coupled receptors have also been identified, such as calcimimetics and calcilytics, that shift calcium concentrationresponse curves at the calcium-sensing receptor to the left and right, respectively (24) . In addition, a number of small molecules, peptides and modified peptides are also known to have substantial effects on neurophysiology, such as enkephalins and conotoxins. Peptides that modulate the function of putative ethanol targets have also been identified and shown to alter ethanol-induced effects (25, 26) . For example, the octapeptide NAPVSIPQ antagonizes ethanol inhibition of L1-mediated cell adhesion and is protective against ethanol-induced embryotoxicity (25) .
Previous work used phage display to identify novel peptides demonstrating high affinities for their intended targets and that acted orthosterically as either agonists at the thrombin receptor (27) or antagonists at the urokinase receptor (28) . In addition, Li et al. (29) used a peptide library to identify a peptidergic antagonist of the NMDA receptor. In recent years there has been increasing interest in the development of novel therapeutics that act at allosteric sites rather than as orthosteric agonists or antagonists binding at the site used by the endogenous ligand. We reasoned that commercially-available phage display technology could be used to identify specific allosteric modulators acting to either enhance or inhibit GlyR function; i.e., compounds that left-shift or right-shift glycine concentrationresponse curves while having no effects on their own. The peptides we identified acted as allosteric agonists or inverse agonists since some enhanced the effects of glycine (eg. D12-116) while others produced inhibition (eg. D12-106).
Peptides have several characteristics that make them excellent candidates as experimental and therapeutic agents. Along with the potential for high target specificity, the small sizes of peptides allows for greater tissue penetration. Peptides have lower manufacturing costs than most proteins and antibodies and show reduced interactions with the immune system (30). However, peptides have traditionally been discounted as viable drugs due to their low bioavailablilties and general inability to cross the blood-brain barrier (31). In recent years, this view has begun to change, as new technologies have arisen to overcome these limitations. Cell-penetrating peptides have long been used to deliver drugs into cellular cytoplasm, but recently this technology has also been used to target bioactive peptides to brain tissue (32). Nanoparticles, a more recently developed technology, have also been highly successful in delivering systemically administered peptides into brain tissue at pharmacologically-relevant concentrations (33). Efforts are also being made to improve the oral delivery of peptides in order to increase their marketability as therapeutic agents (34).
In our studies, we modified common phage display techniques to identify allosteric modulators of the GlyR. Our approach utilizes the cellular expression of the target protein rather than scaffolding of a purified target. This allows for selection in the native environment of the target and eliminates concerns about mis-folding of the target protein. As a result, our peptides only have the opportunity to bind in the extracellular region of the target. Since none of the peptides tested thus far acted as agonists when applied alone, peptides may not be able to bind at the inter-subunit orthosteric glycine binding site (1) to directly activate the GlyR. In the positive selection portion of the phage display screen we expressed GlyR in HEK 293 cells in the absence of exogenously-added glycine, so we assume that selection occurred against GlyR in the closed channel state, since these receptors do not activate spontaneously. To circumvent possible concerns about cell-type specific binding of our peptides, we used receptors expressed in HEK 293 cells for panning but switched to GlyR expressed by Xenopus oocytes for the functional tests.
The wide diversity of peptides identified in our panning screen suggests that a more stringent negative control during phage panning might increase peptide specificity. For example, expressing one or both ρ1 or α1β2γ2S GABA receptor subtypes in the negative selection portion of the panning procedure would be expected to remove those peptides that bind to both GABA and glycine receptors, such as D12-106 and D12-124 ( Figs. 1 and 2) . Another possibility would be to attempt to identify peptides that bind only to specific GlyR subunits by expressing the α2 and/or α3 GlyR subunits in the negative selection when searching for α1-specific peptides.
In summary, by pairing a high throughput peptide screen with a standard electrophysiological test, we identified and characterized novel, specific peptide allosteric modulators of the GlyR. Other approaches to rapidly identify channel modulators have been developed (35); however, our method is easily transferable to other channel targets and has minimal set-up requirements. This approach could be modified for almost any target expressed in an adhering cell system, and is particularly useful for channels or receptors that currently lack specific allosteric modulators. GABA A receptor function. D12-106 had no effect on the holding currents of oocytes expressing the GABA A GlyR when it was applied alone for 30 seconds and minimally inhibited the effects of GABA when it was co-applied with EC10 GABA. (b) Sample tracing showing a lack of effect of a 30 µM concentration of peptide D12-133 on glycine α1β2γ2S GABA A receptor function. D12-133 also did not affect the holding currents of oocytes in the absence of GABA and had no effect when it was co-applied with EC10 GABA. (c) Percent changes in EC10 GABA responses produced by 30 µM concentrations of D12 peptides pre-applied for 30 sec before also being co-applied with EC10 GABA to α1β2γ2S receptors. None of these acted as agonists in directly activating the receptor and had minimal to no effects in the presence of EC10 GABA. Data are expressed as the mean ± S.E.M of 2-6 oocytes obtained from at least two frogs. 
